Revenue: The sum of all revenue fields included for a company's operating activities.
Recursion Pharmaceuticals, Inc. (RXRX) had Revenue of $58.84M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
|
Revenue |
$58.84M |
$-463.66M |
|
$45.24M |
|
$13.60M |
|
$537.84M |
|
$-479.00M |
|
$14.22M |
|
$-464.79M |
|
$-464.79M |
|
$-463.66M |
|
$-463.66M |
|
$-463.66M |
|
$-463.66M |
|
$-479.00M |
|
$-442.51M |
|
274.21M |
|
274.21M |
|
$-1.69 |
|
$-1.69 |
|
| Balance Sheet Financials | |
$714.27M |
|
$141.06M |
|
$734.33M |
|
$1.45B |
|
$187.47M |
|
$19.02M |
|
$226.34M |
|
$413.82M |
|
$1.03B |
|
$550.05M |
|
$1.03B |
|
396.80M |
|
| Cash Flow Statement Financials | |
$-359.17M |
|
$260.06M |
|
$304.12M |
|
$401.43M |
|
$603.02M |
|
$201.60M |
|
$81.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.81 |
|
-- |
|
-- |
|
0.02 |
|
0.03 |
|
23.12% |
|
-814.09% |
|
-814.09% |
|
-752.07% |
|
-789.93% |
|
-788.02% |
|
$-372.87M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
1.20 |
|
304.99 |
|
-44.81% |
|
-84.29% |
|
-32.01% |
|
-44.00% |
|
$2.61 |
|
$-1.36 |
|
$-1.31 |
|